Enterolactone-d6

Enterolactone-d6 is the deuterium labeled Enterolactone. Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity[1]. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis[2].

Product Specifications

CAS Number

[104411-11-2]

UNSPSC

12352005

Target

Apoptosis; Endogenous Metabolite; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Others

Field of Research

Cancer

Purity

95.0

Solubility

DMSO : 30 mg/mL (ultrasonic; warming)

Smiles

C([C@H]1[C@H](CC2=C(C(O)=C(C=C2[2H])[2H])[2H])C(=O)OC1)C3=C(C(O)=C(C=C3[2H])[2H])[2H]

Molecular Formula

C18H12D6O4

Molecular Weight

304.37

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Bigdeli B, et al. Enterolactone: A novel radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis. Toxicol Appl Pharmacol. 2016;313:180-194.|[3]Mali AV, et al. Enterolactone modulates the ERK/NF-κB/Snail signaling pathway in triple-negative breast cancer cell line MDA-MB-231 to revert the TGF-β-induced epithelial-mesenchymal transition. Cancer Biol Med. 2018;15 (2) :137-156.